
Mulligan Lab Publications
Learn more about the research being performed in the Mulligan Lab by reading the latest papers published by principal investigator Mark J. Mulligan, MD, and his team.
Selected Publications
Partial Resistance of SARS-CoV-2 Delta Variants to Vaccine-elicited Antibodies and Convalescent sera
iScience. 2021 Oct 24; 103341
Methotrexate Hampers Immunogenicity to BNT162b2 mRNA COVID-19 Vaccine in Immune-Mediated Inflammatory Disease
medRxiv : the preprint server for health sciences. 2021 May 12;
Evaluation of Immune Response and Disease Status in SLE Patients Following SARS-CoV-2 Vaccination
Arthritis & rheumatology. 2021 Aug 04;
Knowledge and Attitudes Toward Covid-19 and Vaccines Among a New York Haredi-Orthodox Jewish Community
Journal of community health. 2021 Dec ; 46:1161-1169
B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies
MBio. 2021 Jul 27; e0138621
Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes
MBio. 2021 Jun 01; e0069621
The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in non-human primates
Science translational medicine. 2021 05 12; 13:
Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults
Nature. 2020 Oct ; 586:589-593